Asset profile
Daplusiran/Tomligisiran Dose Level 1
RNA / oligonucleotide
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
41 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 41 same-indication; 17 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Daplusiran / Tomligisiran Dose Level 1: this drug | Phase 2 | RNA / oligonucleotide | — | ||
| Adefovir Dipivoxil (Hepsera) | Approved | Small molecule | — | ||
| Entecavir (Baraclude) | Approved | Small molecule | — | ||
| Hepatitis B Immune Globulin (HepaGam B) | Approved | Small molecule | — | ||
| Interferon Alfa-2b (Intron A) | Approved | — | Type I interferon receptor | ||
| Lamivudine (Epivir-HBV) | Approved | — | — | ||
| Peginterferon Alfa-2a (Pegasys) | Approved | — | Type I interferon receptor | ||
| Telbivudine (Tyzeka) | Approved | — | — | ||
| Tenofovir Alafenamide (Vemlidy) | Approved | Small molecule | — | ||
| Tenofovir Disoproxil Fumarate (Viread) | Approved | Small molecule | HIV reverse transcriptase (RT) | ||
| Diluted I.V.-Hepabig inj(GC5103) | Phase 3 | Biologic (subtype unspecified) | — | ||
| Envafolimab | Phase 3 | Monoclonal antibody | PD-L1 | ||
| Hepalatide | Phase 3 | Peptide | NTCP | ||
| Human Hepatitis B Immunoglobulin (Hepatect®CP / Zutectra®) | Phase 3 | Small molecule | — | ||
| Tenofovir Amibufenamide (Hengmu) | Phase 3 | Small molecule | — | ||
| TQA3605 | Phase 3 | — | — |
…and 26 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
May 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.